Clinical Trial Update: A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label study evaluating the safety, tolerability, PK and anti-tumor activity of YH42946 in non-small cell lung cancer and other solid tumors; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• YH42946

Snippet

Sponsor: Yuhan Corporation | Conditions: NSCLC (Non-small Cell Lung Cancer), Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING